Novartis Expects Zelnorm U.S. Approval Despite EU Filing Withdrawal
Novartis continues to expect U.S. approval of Zelnorm (tegaserod) despite problems with the marketing application for the irritable bowel syndrome therapy in Europe.
Novartis continues to expect U.S. approval of Zelnorm (tegaserod) despite problems with the marketing application for the irritable bowel syndrome therapy in Europe.